<DOC>
	<DOCNO>NCT00811408</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Drugs cidofovir may make tumor cell sensitive radiation therapy . Giving cidofovir together radiation therapy chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose cidofovir treat patient stage IB , stage II , stage III , stage IVA cervical cancer receive chemotherapy together radiation therapy .</brief_summary>
	<brief_title>Cidofovir Treating Patients With Stage IB , Stage II , Stage III , Stage IVA Cervical Cancer Who Are Receiving Chemotherapy Radiation Therapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose cidofovir give radiosensitizer patient stage IB-IVA cervical cancer undergo concurrent chemoradiotherapy . Secondary - Evaluate influence treatment expression mRNA codon HPV oncoproteins E6 E7 . - Determine rate local control . OUTLINE : This dose-escalation study cidofovir . Patients receive cidofovir IV weekly 2 week prior begin radiotherapy biweekly radiotherapy . Patients undergo external pelvic radiotherapy 5 week . Beginning ≤ 2 week later , patient undergo utero-vaginal brachytherapy . Some patient may also undergo second course external radiotherapy parametrium and/or lymph node ≤ 3 day brachytherapy . Patients also receive concurrent carboplatin IV weekly external radiotherapy brachytherapy . Biological expression HPV oncoproteins E6 E7 analyze treatment .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Precancerous Conditions</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cidofovir</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis squamous cell carcinoma adenocarcinoma cervix Stage IB2 ( &gt; 4 cm ) , II , III , IVA disease No lumboaortic metastasis Initial tumor must HPVpositive PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy &gt; 3 month ANC &gt; 2,000/mm^3 Platelet count &gt; 100,000/mm^3 Hemoglobin ≥ 9 g/dL Transaminases &lt; 1.5 time upper limit normal ( ULN ) Alkaline phosphatase &lt; 1.5 time ULN Bilirubin &lt; 1.5 time ULN Creatinine &lt; 1.5 time ULN Creatinine clearance ≥ 55 mL/min Proteinuria &lt; 2 g/L Not pregnant Negative pregnancy test No renal disease No concurrent active infection No prior concurrent psychiatric illness No history cancer except basal cell carcinoma No active infection serious illness would prevent patient receive study treatment No known psychological , familial , social , geographic reason would preclude clinical monitoring PRIOR CONCURRENT THERAPY : No prior radiotherapy chemotherapy More 30 day since prior experimental drug</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>human papilloma virus infection</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage II cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
</DOC>